Shoulder arthroplasty in sickle cell patients with humeral head avascular necrosis

2007 ◽  
Vol 16 (2) ◽  
pp. 129-134 ◽  
Author(s):  
Michelle W. Lau ◽  
Morey A. Blinder ◽  
Kimberly Williams ◽  
Leesa M. Galatz
Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 3809-3809
Author(s):  
Michelle W. Lau ◽  
Leesa M. Galatz ◽  
Kimberly Williams ◽  
Morey A. Blinder

Abstract Avascular necrosis (AVN) of the humeral head is a debilitating complication of sickle cell disease (SCD) estimated to occur in ~5% of patients for which the optimal therapy is not well defined. Although shoulder replacement is often used for AVN in other settings, little information is available about the outcome of shoulder arthroplasty in this population. In this study, medical records, radiographs, and pre-operative assessment scores of eight adult patients with sickle cell disease were reviewed. Post-operative assessment scores and radiographs were prospectively collected by an independent observer at follow-up appointments. All eight patients had >2 years of follow up. The mean age of the patients at the time of surgery was 37 years old and there were 4 males and 4 females. Six of the patients had Hgb SS, one had Hgb SC and one had Hgb Sβ+ thalassemia. The average duration of symptoms prior to surgery was 26 months. Based on pre-operative shoulder radiographs, 5 of 7 evaluable patients had grade 3 or greater disease. Seven of eight patients had a hemiarthroplasty and one patient had a total arthroplasty. The mean follow up was 51 months. Complications included two episodes of sickle cell crises in the immediate post-operative period, and one intraoperative rotator cuff tear. One patient developed stiffness that required arthroscopic capsular release 22 months after his initial surgery. No infections were seen in the operated shoulder and no shoulder revisions were performed. At the most recent follow-up, the average American Shoulder and Elbow Society (ASES) score improved 31 points, indicating substantial functional improvement (J Shoulder Elbow Surg. 3(6):347–352, 1994). However, only 25% of the patients reported improvement in pain as assessed by a visual analog scale. While two patients had dramatic improvements in all aspects of our outcome measures, two other patients had decreased functional capacity with no improvement in pain. Radiographs at the most recent follow up revealed slight loosening of the prosthetic stem in one patient but no other radiographic complications. In conclusion, shoulder arthroplasty provides improvements in range of motion and joint function in the majority of patients. However, pain relief is less predictable, suggesting that other causes of sickle cell related pain are occuring. Nevertheless, given the limited options available for the treatment of AVN in sickle cell patients who have failed conservative approaches, shoulder arthroplasty is a reasonable treatment option.


2018 ◽  
Vol 14 (2) ◽  
pp. 225-225 ◽  
Author(s):  
M. Tyrrell Burrus ◽  
Jourdan M. Cancienne ◽  
Jeffrey D. Boatright ◽  
Scott Yang ◽  
Stephen F. Brockmeier ◽  
...  

2021 ◽  
pp. rapm-2021-102842
Author(s):  
Jocelyn Ying-Ah Wong ◽  
Sang Le ◽  
Carl Lo ◽  
Andrew Costandi ◽  
Vasili Chernishof ◽  
...  

BackgroundAvascular necrosis (AVN) can impact up to 50% of patients with sickle cell disease (SCD) and can result in significant pain, decline in physical function and decreased quality of life. While hyaluronic acid (HA) has been used in the adult population for shoulder osteoarthritic pain, we present the first published pediatric case of HA injections in the glenohumeral joint, used to improve function and pain control.Case presentationThe patient is a 12-year-old woman with SCD, who suffered from chronic pain due to AVN of the humeral and femoral head. Despite engaging in a multidisciplinary pain management plan, she continued to have severe decline in physical functioning and became a wheelchair user. As a result, she was scheduled for a right total hip arthroplasty, which necessitated aggressive postoperative therapies using the glenohumeral joint. To improve this pain and to facilitate postoperative recovery, the patient underwent 4 weekly HA injections into the glenohumeral joint. Over a 2-month period, the patient was able to improve physical functioning, decrease opiate use and participate in all postoperative therapies.ConclusionConservative options to improve functioning and pain are especially important in pediatric patients where it may be desirable to delay surgical interventions until skeletal maturity. Our case report demonstrates the benefits of intra-articular HA as part of a multidisciplinary pain management plan to improve function and decrease pain related to AVN of the humeral head. Future studies should assess the long-term benefits of HA injections for AVN in the setting of SCD.


2005 ◽  
Vol 14 (2) ◽  
pp. 114-120 ◽  
Author(s):  
Pierre Mansat ◽  
Lutz Huser ◽  
Michel Mansat ◽  
Yves Bellumore ◽  
Michel Rongières ◽  
...  

2008 ◽  
Vol 17 (5) ◽  
pp. 689-694 ◽  
Author(s):  
Brian T. Feeley ◽  
Stephen Fealy ◽  
David M. Dines ◽  
Russell F. Warren ◽  
Edward V. Craig

2018 ◽  
Vol 2 ◽  
pp. 247154921877844
Author(s):  
Stephen P Maier ◽  
Cesar D Lopez ◽  
Zachary J Bloom ◽  
Brian B Shiu ◽  
Djuro Petkovic ◽  
...  

Introduction Lesser tuberosity osteotomy (LTO) is an attractive option for subscapularis management during anatomic shoulder arthroplasty due to the biomechanical strength and reliable bone-to-bone healing. Patients with humeral head avascular necrosis (AVN) may have compromised bone healing, and the outcomes of LTO during AVN are unknown. Methods A retrospective consecutive case series of 6 patients with Cruess grade 4 or 5 humeral head AVN who underwent anatomic shoulder arthroplasty with LTO from 2010 to 2016 was performed. Postoperative radiographic evaluation for LTO healing at 6 months was analyzed, and clinical outcomes at latest follow-up, including range of motion (ROM), strength, and pain were studied.> Results Average age was 50.3 years. AVN was secondary to sickle cell in 1 patient, steroid use for systemic lupus erythematosus in 4, and chronic alcoholism in 1. By 6 months after arthroplasty, 100% had radiographically united and healed LTO. Patients averaged 140 ± 21° of active forward elevation and 42 ± 7° of active external rotation. Patients reported an improvement in visual analogue scale pain from 8.3 preoperatively to 3.8 postoperatively. All patients had a normal abdominal compression test. No patients required revision surgery. Conclusion The use of LTO during anatomic shoulder arthroplasty for AVN has an excellent bony healing rate with improvements in pain, ROM, and strength. The diseases that cause humeral head AVN do not negatively influence LTO healing outcomes during anatomic shoulder replacement. Level of Evidence IV Case Series


2017 ◽  
Vol 14 (1) ◽  
pp. 2-8 ◽  
Author(s):  
M. Tyrrell Burrus ◽  
Jourdan M. Cancienne ◽  
Jeffrey D. Boatright ◽  
Scott Yang ◽  
Stephen F. Brockmeier ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document